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ABSTRACT
In the past few years, multiple targeted therapies and immunotherapies including 
second generation immunomodulatory drugs (pomalidomide) and proteasome 
inhibitors (carfilzomib, ixazomib), monoclonal antibodies and checkpoint inhibitors 
were approved for the treatment of myeloma or entered advanced phases of clinical 
testing. These agents showed significant activity in advanced myeloma and increased 
the available treatment strategies.
Pomalidomide is well-tolerated and effective in patients with relapsed/refractory 
multiple myeloma who have exhausted any possible treatment with lenalidomide and 
bortezomib. Carfilzomib, a second-generation proteasome inhibitor, is active as a 
single agent and in combination with other anti-myeloma agents. Ixazomib is the first 
oral proteasome inhibitor to be evaluated in myeloma and is associated with a good 
safety profile and anti-myeloma activity in relapsed/refractory patients, even in those 
refractory to bortezomib. Monoclonal antibodies and immune checkpoint inhibitors 
are likely to play a major role in the treatment of myeloma over the next decade.
In phase 3 studies, triplet regimens based on these agents combined with a 
backbone therapy (including lenalidomide, pomalidomide or bortezomib) were more 
efficacious than doublet regimens in patients with relapsed/refractory multiple 
myeloma, with limited additional toxic effects.
This paper aims to provide an overview of the recent use of these agents for the 
treatment of myeloma, in particular focusing on the role of multi-agent combinations.
INTRODUCTION
Multiple myeloma (MM) is a neoplastic disease 
characterized by the proliferation of abnormal bone 
marrow plasma cells and immunoglobulin or light chain 
overproduction, which can cause end-organ damage.
Before 2000, the median survival of patients with 
newly diagnosed MM was approximately 2.5 years. First-
generation novel agents, namely bortezomib, thalidomide, 
and lenalidomide, and the introduction of autologous stem 
cell transplantation (ASCT) have substantially improved 
overall survival (OS), which currently ranges from 5 to 
7 years [1].
Nevertheless, long-term control of the disease 
remains still elusive, and most patients relapse or become 
refractory to existing therapies. Patients with disease 
refractory to both immunomodulatory drugs (IMiDs) and 
bortezomib have a median event-free-survival (EFS) and 
OS of only 5 and 9 months, respectively [2].
As such, the search for newer agents with different 
mechanisms of action to overcome drug-resistance has 
led to the development of second-generation IMiDs and 
proteasome inhibitors (PIs), histone deacetylase inhibitors 
(HDACs), Akt and mTOR inhibitors. In addition, 
monoclonal antibodies (MoAbs) have recently enriched 
the treatment armamentarium against MM.
Here, we will review the clinical activity of the 
newer generation IMiDs and PIs, HDACs and MoAbs, 
giving an in-depth insight of their possible application and 
their role when used in combination.
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SUMMARY OF THE CLINICAL RESULTS
Second-generation immunomodulatory drug
Pomalidomide
Pomalidomide is a second-generation IMiD with 
a structure similar to thalidomide and lenalidomide. 
Pomalidomide exerts its antitumor activity by anti-
proliferative and pro-apoptotic effects on plasma cells, by 
bone marrow microenvironment modulation (anti-angiogenic 
and anti-inflammatory effects) and by immunomodulation 
(increase in T and NK cell activity, suppression of regulatory 
T cells) [3–7].
Previous phase I and II studies of pomalidomide 
(2 to 4 mg), either alone or in combination with 
dexamethasone, showed overall response rate (ORR) 
ranging from 26% to 65% and a median progression-
free survival (PFS) from 3 to 13 months, depending on 
the number of prior therapies (median 2 to 6) and the 
refractoriness to bortezomib and lenalidomide [8–13].
Of note, the Intergroupe Franconphone du 
Myelome (IFM) tested two schedules of pomalidomide-
dexamethasone in a phase II study, where pomalidomide 
was given either for 21 days of a 28-day cycle or 
continuously (28/28). No differences in terms of ORR 
and outcomes were reported but patients receiving 
pomalidomide continuously reported a higher rate of 
infections (19% in the 21/28 arm vs 27% in the 28/28 
arm) and pneumonia (7% in the 21/28 arm 19.5% in the 
28/28 arm). Consequently, the investigators recommended 
the 21/28 schedule of pomalidomide-dexamethasone for a 
better marrow recovery [14].
In the phase III MM-003 trial, pomalidomide-
dexamethasone (4 mg, 21/28) was formally compared to high-
dose dexamethasone (HiDex) in heavily pre-treated patients 
mostly refractory to both lenalidomide and bortezomib after 
a median of 5 prior lines of therapy (Table 1). Pomalidomide-
dexamethasone induced a higher ORR than HiDex (21% 
vs 3%; p<0.001) and significantly prolonged median PFS 
(4 vs 2 months; p<0.001) and OS (not reached vs 8 months, 
p<0.001) [15]. Major toxicities are summarized in Table 2.
Based on the positive results obtained with this new 
agent, in February 2013, the Food and Drug Administration 
(FDA) and subsequently the European Medicines Agency 
(EMA) granted accelerated approval to pomalidomide 
for the treatment of patients with MM who have received 
at least two prior therapies, including lenalidomide and 
bortezomib, and experienced disease progression on or 
within 60 days of completion of the last therapy.
Second-generation proteasome inhibitors
Carfilzomib
Carfilzomib is a second-generation, epoxyketone PI 
that binds selectively and irreversibly to the constitutive 
proteasome and immunoproteasome [16, 17].
This drug was initially tested as single agent in the PX-
003-A1 study, where it was given twice-weekly at the dose of 
27 mg/m2. Patients with relapsed/refractory MM (RRMM) 
who had received a median of 5 prior lines of therapy - 
including bortezomib, thalidomide and lenalidomide - were 
enrolled in the trial. The ORR was 24% and the duration of 
response (DOR) and OS were 8 and 16 months, respectively 
[18, 19]. In 2015, based on this pivotal study, carfilzomib 
was granted approval in the US for the treatment of patients 
with RRMM who had received at least 2 prior lines of 
therapy including bortezomib and an IMiD. The approved 
dose and schedule of carfilzomib is a twice-weekly, 10-min 
intravenous infusion on days 1, 2, 8, 9, 15, and 16 of 28-day 
cycles (starting dose: 20 mg/m2 [days 1 and 2 of cycle 1]; 
escalated to a target dose of 27 mg/m2 thereafter).
Subsequently, carfilzomib was compared with 
bortezomib in the relapse setting. In the randomized phase 
III study ENDEAVOR, carfilzomib plus dexamethasone 
(Kd) demonstrated a clinically meaningful and statistically 
significant two-fold improvement in median PFS compared 
with bortezomib plus dexamethasone (Vd; 19 vs 9 months; 
hazard ratio [HR]: 0.53; 95% confidence interval [CI]: 0.44-
0.65; P<.0001). Higher and deeper responses were observed 
with Kd vs Vd across all cytogenetic subgroups [20, 21]. 
In particular, Kd had a favorable benefit-risk profile in 
high-risk RRMM, and was superior to Vd, regardless of 
baseline cytogenetic risk status [22]. More recently, Kd has 
demonstrated 7.6-month longer OS than Vd (median OS 
47.6 months for Kd versus 40.0 for Vd, HR=0.79; 95 % 
CI: 0.65 – 0.96; p=0.01), regardless of prior bortezomib 
therapy (HR 0.75 for no prior bortezomib; HR 0.84 for prior 
bortezomib) [23].
The phase I-II CHAMPION-1 study evaluated 
escalated doses of once-weekly carfilzomib in combination 
with dexamethasone in patients with RRMM. Interestingly, 
the maximum tolerated dose (MTD) of carfilzomib was 
70 mg/m2, resulting in an ORR of 77% and a median PFS 
of 12.6 months [24].
Because of the impressive results, the dose and 
schedule of carfilzomib used in the CHAMPION-1 
trial (70 mg/m2) is currently being compared with the 
regulatory-approved carfilzomib dose and schedule 
(27 mg/m2 administered twice-weekly) in the ongoing 
phase III ARROW study [25].
Ixazomib
Ixazomib (MLN9708) is the first oral PI to be 
introduced in the treatment of MM. It is a boronic acid 
that is rapidly hydrolyzed in water and converts into 
MLN2238. The biologically active form MLN2238 inhibits 
the chymotrypsin-like proteolytic site of the proteasome. 
in vitro studies have shown activity of ixazomib against 
MM cells, even in those resistant to bortezomib [26].
In a phase I trial, single agent ixazomib showed 
clinical activity in 60 patients with RRMM, with 27% 
ORR at the MTD (2.97 mg once-weekly) [27].
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A phase II trial investigated single agent ixazomib 
in 33 RRMM patients at the dose of 5.5 mg in 3 or 
4-week schedule. Approximately two thirds of patients 
required the addition of dexamethasone for either 
suboptimal response or progression. Results with 
Ixazomib plus dexamethasone were promising, with an 
ORR of 34% and a median EFS of 11.5 months, and no 
differences were found according to prior exposure to 
bortezomib [28].
Moreover, two doses of ixazomib (4 and 5.5 mg) 
given once-weekly (on days 1, 8 and 15 of a 28-day 
cycle) combined with dexamethasone showed to be safe 
and effective in RRMM patients. Ixazomib at the dose 
of 5 mg induced deeper responses (ORR: 38% vs 52%) 
but resulted in a higher rate of grade ≥3 adverse events 
(21% vs 54%) [29].
The promising activity of ixazomib as single 
agent, the oral administration, and its safety profile led 
to investigate its role as a maintenance agent both in the 
transplant (NCT02181413) and in the non-transplant 
(NCT02312258) settings in two ongoing phase III trials.
Monoclonal antibodies
Elotuzumab
Elotuzumab is a humanized monoclonal IgG1 
antibody directed against human CS1 (also known as 
SLAMF7), a cell surface glycoprotein highly expressed 
on MM cells, and at a lower level on normal plasma 
cells, NK cells and other T-cells [30]. CS1 mediates 
the adhesion of MM cells to the bone marrow stromal 
cells, granting their proliferation and preventing 
apoptosis [31]. By binding CS1, elotuzumab inhibits 
the stimulatory effects of the bone marrow on MM 
cells; furthermore, it exerts anti-MM activity via ADCC 
mediated by NK cells [30].
Table 2: Main toxicities of novel agent-combinations in phase III trials for relapsed or refractory multiple myeloma
Trials
Grade 3-4
Adverse events
(AE)
MM-003
(pomalidomide-
dexamethasone)
ENDEAVOR
(carfilzomib-
dexamethasone)
ASPIRE
(carfilzomib-
lenalidomide-
dexamethasone)
TOURMALINE-
MM1
(ixazomib-
lenalidomide-
dexamethasone)
CASTOR
(daratumumab-
bortezomib- 
dexamethasone)
POLLUX
(daratumumab-
lenalidomide- 
dexamethasone)
ELOQUENT-2
(elotuzumab- 
lenalidomide- 
dexamethasone)
Haematological Anemia 33%
Neutropenia 48%
Thrombocitopenia 
22%
Anemia 14%
Neutropenia 2%
Thrombocitopenia 
8%
Anemia 18%
Neutropenia 30%
Thrombocitopenia 
17%
Anemia 9%
Neutropenia 22%
Thrombocitopenia 
19%
Anemia 14%
Neutropenia 13%
Thrombocitopenia 
45%
Lymphocitopenia 
10%
Anemia
Neutropenia
Thrombocitopenia
Anemia 19%
Neutropenia 34%
Thrombocitopenia 
19%
Lymphocitopenia: 
77%
Non-
haematological 
Pneumonia 14%
Fatigue 5%
Hypertension 9%
Dyspnea 5%
Cardiac failure 
5%
Hypertension 4%
Cardiac failure 
4% Dyspnea 3%
Diarrhea 6%
Rash 5%
Pneumonia 8%
Fatigue 6%
Diarrhea 5%
Infusion related 
reaction 5%
Pneumonia 8%
Hypertension 7%
Sensory 
peripheral 
neuropathy 5%
Infusion related 
reaction 5%
Fatigue: 8%
Rash: 5%
Table 1: Efficacy of phase-III trials for relapsed or refractory multiple myeloma
Trials MM-003
(pomalidomide-
dexamethasone 
vs. high-dose-
dexamethasone)
ENDEAVOR
(carfilzomib-
dexamethasone 
vs. bortezomib-
dexamethasone)
ASPIRE
(carfilzomib-
lenalidomide-
dexamethasone 
vs. 
lenalidomide-
dexamethasone)
TOURMALINE-
MM1
(ixazomib-
lenalidomide-
dexamethasone 
vs. placebo-
lenalidomide-
dexamethasone)
CASTOR
(daratumumab-
bortezomib- 
dexamethasone 
vs. bortezomib-
dexamethasone)
POLLUX
(daratumumab-
lenalidomide- 
dexamethasone 
vs. 
lenalidomide-
dexamethasone)
ELOQUENT-2
(elotuzumab- 
lenalidomide- 
dexamethasone 
vs. lenalidomide- 
dexamethasone)
Overall-
response-
rate (%)
31 vs. 10 77 vs. 63 87.1 vs. 66.7 78.3 vs 71.5 83 vs 63 93% vs 76% 79 vs. 66
Median 
progression-
free-survival 
(months)
3.8 vs. 1.9
HR 0.41 (95% 
CI, 0.32–0.53)
18.7 vs. 9.4
HR 0.53 (95% CI, 
0.44–0.65)
26.3 vs. 17.6
HR 0.69 (95% 
CI, 0.57-0.83)
20.6 vs 14.7
HR 0.74 (95% CI, 
0.59-0.94)
NR vs 7.2
HR 0.39 (95% 
CI, 0.28-0.53)
NA
HR 0.37 (95% 
CI, 0.27-0.52)
19.4 vs 14.9
HR 0.70 (95% CI, 
0.57-0.85)
NR, not reached; NA, not available; HR, hazard ratio; CI, confidence interval.
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The first-in-human trial of elotuzumab as single 
agent was conducted in 35 RRMM patients [32]. This agent 
appeared to be well tolerated, and the MTD was not reached 
at the maximum dose tested (20 mg/kg every other week). 
The main adverse events were infusion-related reactions 
(IRR), generally mild to moderate, occurring during the first 
dose of elotuzumab. When the protocol was amended for 
premedication before the infusion of elotuzumab, no grade 
3-4, nor serious IRR, were reported. Despite the appealing 
safety profile, single agent elotuzumab did not induce 
objective responses, and 26.5% of patients achieved a stable 
disease (SD); this evidence supported further investigation 
of elotuzumab in combination with other novel agents in 
phase II and III trials.
Anti-CD 38 monoclonal antibodies
CD38 is a type II transmembrane glycoprotein 
exerting receptor-mediated adhesion and signaling 
functions [33, 34]. It is expressed at relatively low levels 
on lymphoid and myeloid cells, as well as on other 
non-hematological tissues, while it is highly expressed 
on malignant plasma cells, thus becoming a potential 
therapeutic target [35].
Three anti-CD38 MoAbs were recently developed: 
the chimeric Isatuximab (SAR650984), and the fully 
humanized Daratumumab (DARA) and MOR202 (MOR) 
[36]. Each MoAb targets a distinct epitope on CD38, with 
different mechanisms of action.
Daratumumab
Daratumumab is a fully human IgG1 MoAb 
targeting a specific epitope of CD38 on the surface of 
MM cells [36]. It exerts its anti-myeloma effect through 
the activation of complement-dependent cytotoxicity 
(CDC), antibody-dependent cell mediated cytotoxicity 
(ADCC) and antibody-dependent cellular phagocytosis 
(ADCP); furthermore, daratumumab is able to induce 
direct apoptosis of myeloma cells and modulation of the 
enzymatic activity of CD38 [36–40].
The GEN501 study was the first-in-human trial with 
daratumumab. In that study, the MTD of daratumumab 
was not reached, with dose levels up to 24 mg/kg. The 
ORR was 36% in heavily pre-treated patients who 
received daratumumab at a dose of 16 mg/kg. Efficacy 
was dose-related, indeed the ORR was 10% with the 8 mg/
kg dose and 35% with the higher 16 mg/kg dose [41, 42].
In the phase II SIRIUS trial, daratumumab at the 
dose of 16 mg/kg, was tested in 106 patients with a median 
of 5 prior therapies; a vast majority of patients had failed 
lenalidomide and bortezomib, many were refractory to 
pomalidomide and carfilzomib. Daratumumab induced 
an ORR of 29%, a median PFS of 3.7 months and a 
median OS of 17.5 months. Of note, the ORR was 21% in 
patients quadruple refractory to bortezomib, lenalidomide, 
pomalidomide, and carfilzomib [43].
In the pooled analysis of GEN501 and Sirius 
trials approximately one third of patients treated with 
daratumumab 16 mg/kg achieved an objective response; 
responses were durable (median DOR: 8 months) and 
independent of the number of prior therapies and renal 
function [44]. The median PFS and OS were 4 and 
20 months, respectively. A remarkable PFS difference was 
observed between responding (≥PR) and non-responding 
patients (median, 15 vs 1 month). Interestingly, a survival 
advantage was reported not only among responding 
patients (median OS NR), but also in patients with a SD or 
minimal response (MR) (median OS 19 months) over non-
responding patients (median OS, 4 months). Any grade 
IRRs occurred in 48% of patients; however, only 3% were 
severe IRR (≥ grade 3-4). IRRs developed during the first 
infusion (96%), with a low rate of reoccurrence during the 
subsequent infusions (7%).
Single agent daratumumab was approved in the US 
in November 2015 by FDA, and subsequently in Europe 
by EMA, for patients with MM who have received at least 
3 prior lines of therapy including a PI and an IMiD or who 
are double-refractory to a PI and an IMiD.
Isatuximab (SAR650984)
Isatuximab (SAR650984) is a chimeric anti-CD38 
antibody generated from immunization with murine 
300-19 cells transfected to express human CD38 [45]. 
Isatuximab induces cell death via ADCC in all the CD38+ 
lines tested, ADCP and CDC in in vitro models. It also 
exerts a pro-apoptotic effect.
Isatuximab was evaluated in a dose escalation study 
(0.3-20 mg/kg) to determine its MTD and safety profile in 
patients with different RR hematological malignancies. In 
18 heavily pre-treated RRMM patients (median number 
of prior therapies of 6), who were treated with ≥10 mg/
kg isatuximab, at least a PR was documented in 33% of 
patients, including a complete response (CR) in 11%. 
IRRs mainly occurred during the first infusion and were 
not severe in grade (1-2). The most common treatment-
emergent toxicities were fatigue (53%) and nausea (35%), 
and the most common drug-related grade 3-4 event was 
pneumonia (8%).
Checkpoint inhibitors
Recently, the interaction between the tumor and 
the immune system has become a highly relevant clinical 
matter. Evidence has emerged that tumor cells may 
impair the immune host system control through different 
pathways, such as the T-lymphocyte associated protein 
4 (CTLA-4) and programme-death 1 (PD-1), blocking 
immune activity by expressing the ligands of immune 
checkpoint receptors. MoAbs directed against ligands and 
the involved receptors allow the reversal of tumor-induced 
down-regulation of T-cells and the enhancement of the 
immune response against neoplastic cells [46].
Two anti-PD1 MoAbs, nivolumab and pembrolizumab, 
and the anti-PDL1, durvalumab, are currently under 
investigation in MM patients. Nivolumab as single agent 
(3 mg/kg) was tested in 27 RRMM patients; no objective 
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responses were observed, however 63% of patients 
achieved disease control (SD) [47]. Pembrolizumab is a 
humanized IgG4 MoAb, directed against PD-1, blocking 
the interaction between PD-1 and PD-L1/PD-L2. 
Pembrolizumab demonstrated effective antitumor activity 
and manageable safety in various cancers [48].
SUMMARY OF DRUG-COMBINATIONS
IMiDs and PIs combinations
New drugs currently under investigation in different 
combinations are summarized in Table 3. The addition of 
the alkylating agent cyclophosphamide to pomalidomide-
dexamethasone (PD) doubled the ORR, from roughly 
30% to 51-65%, and prolonged PFS from approximately 
4 months to 10 months, without adding significant 
toxicities [49, 50].
The pro-apoptotic effect of pomalidomide proved 
to be enhanced by dexamethasone and PIs [12, 51]. Two 
trials explored the activity of pomalidomide, bortezomib 
and dexamethasone (PVD) in patients who had received 
1–4 lines of previous therapy. In the Phase I MM-005 
study the MTD of pomalidomide was established at 4 
mg on days 1–14 in a 28-day cycle [51]. In the cohort 
of 22 patients who received intravenous bortezomib, 71% 
achieved at least a PR and 38% at least a very good partial 
response (VGPR). Neutropenia and thrombocytopenia 
were the most common grades 3–4 adverse events, 
whereas no severe neuropathy was reported. In another 
phase I-II study, the MTD of once-weekly bortezomib, 
associated with pomalidomide (4 mg on days 1-21) and 
dexamethasone (40 mg weekly), was 1.3 mg/m2 [52]. 
Overall, 94% of patients achieved at least a PR including 
56% with at least a VGPR. Neutropenia (36%) was 
the most common severe complication. These studies 
provided the basis for an ongoing, randomized phase III 
study comparing PVD with VD (MM-007 study).
The synergistic activity of IMiDs and PIs led 
physicians to test carfilzomib in combinations with both 
lenalidomide and pomalidomide in the relapse setting.
In a phase I/II study, carfilzomib, lenalidomide, and 
weekly dexamethasone (KRd) was active in patients with 
relapsed disease; the safety profile was consistent with 
the known toxicity of each agent [53, 54]. The promising 
results obtained in the phase I/II trial led to a randomized 
phase 3 study (ASPIRE) evaluating carfilzomib added 
to standard Rd (KRd) as compared to Rd in patients 
with RRMM. KRd resulted in a clinically relevant 31% 
decrease in the risk of disease progression or death and an 
increase of 8.7 months in the median PFS (26.3 months 
in the carfilzomib group vs. 17.6 months in the control 
group). The 2-year OS rate was higher in the carfilzomib 
group (73.3% and 65.0% respectively; HR for death 
0.79; 95% CI, 0.63 to 0.99; P = 0.04). The ORRs were 
87.1% and 66.7% in the carfilzomib and control groups, 
respectively (P<0.001). Adverse events of grade 3 or 
higher were reported in 83.7% and 80.7% of patients in 
the carfilzomib and control groups, respectively; 15.3% 
and 17.7% of patients discontinued treatment owing to 
adverse events [55].
Lenalidomide is widely adopted in the upfront 
setting and pomalidomide proved to be effective also in 
patients relapsed after and/or refractory to lenalidomide. 
In a phase 1 study, a new 3-drug combination consisting 
of carfilzomib, pomalidomide, dexamethasone, was 
tested. Almost all patients were dual-refractory (to 
both lenalidomide and bortezomib). The MTD of the 
regimen in this heavily pretreated patient population 
(median of six lines of prior therapy) was carfilzomib 
27 mg/m2, pomalidomide 4 mg, dexamethasone 40 mg. 
Grade ≥3 non hematological toxicities were congestive 
heart failure, pulmonary embolisms, renal failures, and 
pneumonia. A high response rate of 50% was observed, 
the median PFS was 7.2 months, and the median OS was 
20.6 months [56].
Newer early phase studies are currently evaluating 
carfilzomib in combination with novel compounds such 
as the kinesin spindle protein inhibitor Filanesib or the 
Bruton’s tyrosine kinase inhibitor Ibrutinib, in relapsed/
refractory patients [56, 57].
Preclinical studies indicated a synergistic activity 
of ixazomib with lenalidomide [26]. A phase I/II study of 
ixazomib combined with lenalidomide-dexamethasone 
was designed to determine the safety and efficacy of this 
all oral combination in newly diagnosed MM patients [58]. 
The recommended phase II dose of Ixazomib combined 
with Rd was 2.23 mg/m2 on days 1,8 and 15 of a 28-day 
cycle, which was converted, based on pharmacokinetic 
analysis, to a fixed dose of 4 mg. Ixazomib-Rd showed 
to be well tolerated, and the most frequent toxicities were 
skin adverse events (17%), neutropenia (12%), fatigue 
(9%) and thrombocytopenia (8%). At the recommended 
dose of ixazomib, this combination showed a promising 
efficacy (ORR was 90% with ≥VGPR rate of 62%) in 
both transplant-eligible and -ineligible patients. These data 
provided the rationale for the phase 3 TOURMALINE-
MM1 study assessing ixazomib-Rd versus placebo-Rd in 
772 RRMM patients with 1-3 prior lines of treatment [59]. 
Ixazomib was given at the dose of 4 mg on days 1,8 and 
15, lenalidomide 25 mg on days 1-21 and dexamethasone 
on days 1,8,15 and 22 of 28-day cycles. Despite similar 
ORR (78% vs 72%), Ixazomib-Rd significantly improved 
PFS as compared to Rd (median, 21 vs 15 months; HR 
0.74, p=0.012), while OS data were not mature yet. 
Results favoring Ixazomib-Rd were consistent across 
all analyzed subgroups, including age, ISS, cytogenetic 
abnormalities and previous exposure to PIs. Ixazomib did 
not add significant toxicities to Rd (any ≥ grade 3 adverse 
events: 68% vs 61%) and the most common toxicities 
were hematologic: grade 3-4 thrombocytopenia was more 
common in the Ixazomib arm (19% vs 9%). Any grade 
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peripheral neuropathy was reported in 28% and 21% 
of patients treated with Ixazomib-Rd or placebo-Rd, 
respectively.
Based on those results, in November 2015, ixazomib 
in combination with Rd was granted approval by the 
FDA, and subsequently, by the EMA, for the treatment 
of patients with RRMM who had received at least 1 prior 
therapy.
The high rate of double-refractory (to both 
lenalidomide and bortezomib) MM patients, led 
investigators to combine next-generation PI and IMiDs, 
particularly ixazomib and pomalidomide A phase I/II, 
dose escalation study explored ixazomib (3-4 mg on 
days 1,8 and 15), pomalidomide (2-4 mg on days 1-21) 
and dexamethasone (20-40 mg on days 1,8,15 and 22) 
in a 28-day cycle in double-refractory patients [60]. In 
14 evaluable patients, grade 3-4 neutropenia occurred in 
29% of patients, while 12% of them experienced grade 
3 infections. Low-grade peripheral neuropathy was 
documented in 24% of patients. The ORR was 62% in 13 
evaluable patients. Therefore, the combination ixazomib-
pomalidomide-dexamethasone seems to be safe and 
effective in this subset of patients.
Combinations including histone deacetylase 
inhibitors
Histone deacetylases (HDACs) are a group of 
enzymes involved in the epigenetic control of various 
processes, from cell cycle progression to angiogenesis 
[61–63]. HDAC inhibitors (HDACIs) intervene in the 
regulation of crucial events in myeloma progression, 
causing cell cycle arrest, up-regulating the expression 
of pro-apoptotic proteins, reducing anti-oxidative stress 
defenses and the proteasome activity [64].
Numerous HDACIs have been developed 
(vorinostat, panobinostat, givinostat, romidepsin and 
ricolinostat) and all have been tested for the treatment of 
myeloma patents. However, no significant activity has 
been reported when used as single agent [65–68].
Table 3: New agents currently under investigation
Class Agent Target Combination tested Approval
Proteasome inhibitor Carfilzomib
KTd
KRd
KPd
K-filanesib
Carf-Rd
Ixazomib Ixazomib-RdIxazomib-Pd Ixa-Rd
Immunomodulatory 
drug Pomalidomide
PVD
KPd
Ixazomib-Pd
Dara-Pd
Pembrolizumab-Pd
Durvaumab-Pd
Elo-Pd
Poma-dex
Monoclonal antibody Elotuzumab CS1
Elo-Rd
Elo-Vd
Elo-Pd
Elo-Rd
Daratumumab CD38
Dara-Rd
Dara-Vd
Dara-Pd
Dara-Rd
Dara single agent
SAR CD38 SAR-RdSarVCD
Checkpoint inhibitor Pembrolizumab PD-1 Pembrolizumab-RdPembrolizumab-Pd
Durvalumab PDL-1 Durvalumab-RdDurvalumab-Pd
K, carfilzomib; T, thalidomide; d, dexamethasone; R, lenalidomide; carf, carfilzomib; ixa, ixazomib; poma, pomalidomide; 
elo, elotuzumab; dara, daratumumab; V, bortezomib. A brief review of other innovative compounds including mTOR, MEk, 
BRAF and Akt inhibitors, anti IL-6 and anti KIR agents.
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The combined inhibition of both proteasome and 
aggresome protein degradation pathways has suggested 
HDACIs as the ideal partner for PIs. The promising 
results obtained in phase I and II trials adding vorinostat to 
bortezomib paved the way to the phase III trial comparing 
Vd plus vorinostat or placebo in RRMM patients; [69, 70] 
despite a higher ORR (56% vs 41%), no survival advantage 
was reported for patients receiving vorinostat [71].
A synergistic activity between panobinostat and 
bortezomib-dexamethasone was reported in the phase II 
PANORAMA 2 trial, where the three-drug combination 
was able to induce an objective response among 35% of 
heavily pre-treated RRMM patients [72]. Based on these 
results, the addition of panobinostat to standard Vd was 
formally compared in a phase III trial (PANORAMA 1) 
enrolling 768 RRMM patients. Despite a similar ORR 
(61% vs 55%), responses were deeper with panobinostat-
bortezomib-dexamethasone (PanoVd) as compared to Vd 
(CR, 28% vs 16%); [73] this translated into a median PFS 
(12 vs 8, months) and OS (34 vs 30, months) advantage 
for patients receivng panobinostat. Interestingly, the PFS 
advantage observed in the PanoVd arm was even more 
pronounced in patients previously exposed to both PIs 
and IMiDs (median, 13 vs 5, months) [74]. As expected, 
AEs were more frequent in the PanoVd arm, and 33% 
of patients had to discontinue treatment against 17% in 
the Vd arm. Most frequent AEs were diarrhea (68%), 
thrombocytopenia (67%) and fatigue (57%).
Based on these results, the FDA and EMA approved 
panobinostat for myeloma patients after at least 2 prior 
treatments including IMiDs and PIs.
Combinations including MoAbs
Elotuzumab
Data from preclinical models suggest a synergistic 
activity elotuzumab with bortezomib and lenalidomide, 
probably mediated through the enhancement of 
elotuzumab-mediated ADCC and the stimulation of NK 
cell activity [31, 75].
In a phase II trial in lenalidomide-naive myeloma 
patients with a median of 2 previous therapies, the 
combination of elotuzumab-lenalidomide-dexamethasone 
(EloRd) was feasible and effective, with 85% least PR [76].
In another study, EloRd induced 82% PR, and 
32% at least a VGPR. Prior exposure to novel agents 
or number of prior therapies did not appear to affect 
response rate [77]. No DLTs occurred and the MTD was 
not reached.
Based on these encouraging results, a phase III 
trial comparing the combination EloRd versus Rd was 
conducted (ELOQUENT-2) [78]. Overall, 321 patients 
were assigned to the elotuzumab group and 325 to the 
control group. After a median follow-up of 24.5 months, 
median PFS in the elotuzumab group was 19 versus 
15 months in the control group, with a relative reduction 
of 30% in the risk of disease progression or death 
(p<0.001). Of note, EloRd combination delayed the 
need for subsequent myeloma therapy by a median of 
one year compared to Rd alone [79]. The ORR in the 
elotuzumab group was 79% versus 66% in the control 
group (P<0.001). Common grade 3 or 4 adverse events 
in the two groups were lymphocytopenia, neutropenia, 
fatigue, and pneumonia. Infusion reactions occurred in 
10% of patients in the elotuzumab group and were mostly 
grade 1 or 2.
Elotuzumab was also evaluated in combination with 
bortezomib in a phase I study [80]. No DLTs occurred 
and the MTD was not reached. Forty-eight percent and 
63% of the evaluable patients achieved at least a PR and 
a minimal response, respectively. Adverse events were 
primarily grade 1-2 IRR, observed in 71% of patients. 
A formal comparison between elotuzumab-bortezomib-
dexamethasone (EloVd) and Vd has been recently 
conducted among 150 RRMM patients, and half of them 
had previously received bortezomib [81]. Despite a similar 
ORR (66% vs 63%), a trend towards a better PFS was 
reported in favor of patients receiving EloVd as compared 
to those treated with Vd (median, 10 vs 7 months; HR 
0.72, p=0.09). In a preliminary survival analysis, the 
2-year OS was 73% with EloVd and 66% with Vd. The 
addition of elotuzumab to Vd did not add significant 
toxicities: grade 3-4 adverse events occurred in 71% of 
patients who received EloVd and 60% of those treated 
with Vd; main toxicities were infections (21% vs 13%) 
and thrombocytopenia (9% vs 17%).
Preliminary data from a Spanish phase II trial 
showed a favorable toxicity profile and promising efficacy 
with Elotuzumab combined with thalidomide and low-
dose dexamethasone (EloTd) in the relapse setting [82]. 
Forty heavily pre-treated patients (3prior regimens) 
received EloTd. As per protocol, cyclophosphamide was 
added in 28% of patients because of lack of response or 
due to progression. The main toxicities reported were 
asthenia (any grade, 35%) and peripheral edema (any 
grade, 25%); EloTd was able to induce an objective 
response in 38% of patients, with median PFS and OS of 
4 and 13 months, respectively.
Anti-CD38
Lenalidomide improves the efficacy of MoAbs 
thanks to its ability to enhance ADCC and the activity of 
effector cells (for example, NK cells), and to upregulate 
CD38 expression on MM cells [83, 84].
The combination of daratumumab with lenalidomide 
and dexamethasone (DaraRd) was firstly tested in a phase 
I/II trial enrolling RRMM patients. In the expansion 
phase (32 patients, not lenalidomide refractory and with 
a median of 2 prior lines of therapy), daratumumab was 
administered at the dose of 20 mg/kg. The ORR was 88% 
with 25% of CR (22% sCR) [85].
Based on these results, DaraRd (with daratumumab 
16 mg/kg) was formally compared to standard Rd in 
a phase III trial (POLLUX), enrolling 569 RRMM 
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patients after at least 1 prior regimen. [86] Patients in 
the experimental arm had a significantly lower risk of 
disease progression or death as compared to patients in 
the standard arm (HR 0.32; p<0.001), regardless of the 
number of prior therapies or previous lenalidomide 
exposure. Of notice, a significantly higher proportion of 
patients in the DaraRd group reached minimal residual 
disease (MRD; threshold of 1 tumor cell per 10^5 white 
cells) than those in the Rd group (22% vs 5%; p<0.001). 
The addition of daratumumab to Rd did not affect the 
tolerability of the combination: adverse events leading 
to treatment discontinuation were in fact similar in the 
groups (7% vs 8%).
A twin phase III, randomized study (CASTOR), 
evaluating the benefit of the addition of daratumumab to 
VD in the relapse setting, has been recently published. 
Results are impressive: daratumumab-VD, significantly 
improved median PFS, with 61% reduction in the risk of 
progression (P<0.001) and induced a marked increase in 
ORR (83% vs 63%, P<0.001) and in at least VGPR rate 
(59% vs 29%, P<0.001). As reported in the POLLUX trial, 
the addition of daratumumab significantly increased the rate 
of MRD negativity at all the examined thresholds (1 tumor 
cell per 10^4, 10^5 and 10^6 white cells; p<0.001) [87, 88].
Daratumumab has been also tested in combination 
with next generation novel agents such as carfilzomib and 
pomalidomide. An ongoing phase Ib study is evaluating 
the triplet daratumumab, carfilzomib and dexamethasone 
and will clarify the role of daratumumab in association 
with carfilzomib. Similarly, another study assessed the 
role of daratumumab plus the third-generation IMiD 
pomalidomide (DaraPD) in 77 RRMM with 3.5 median 
prior lines of treatment. Preliminary results are promising, 
as daratumumab did not add significant toxicities to those 
reported with PD, except for IRRs, which occurred in 
61% of patients. In 53 patients evaluable for efficacy, 
ORR was 58.5%, with similar results in the double 
refractory (lenalidomide and bortezomib) population 
(ORR 57.5%) [57].
Another interesting MoAb is Isatuximab 
(SAR650984), which has demonstrated synergistic 
or additive antitumor effects in combination with 
lenalidomide, bortezomib, carfilzomib and melphalan in 
mouse xenograft tumor models. Isatuximab in combination 
with Rd in heavily pre-treated patients (with a median of 
7 prior treatments), reported an ORR of 63% at the dose 
of 10 mg/kg and a reduction in paraprotein of >90% was 
recorded in approximately one-third of patients [89]. The 
vast majority of patients in this study were relapsed or 
refractory to lenalidomide, yet the ORR was 48% in this 
patient subpopulation. The median PFS was 6.2 months, 
yet in patients who had received only 1-2 lines of prior 
therapy (n=7) median PFS had not been reached at data 
cut-off. Notably, responses were also observed in patients 
refractory to bortezomib, carfilzomib or pomalidomide 
[89].
Checkpoint-inhibitors
In preclinical studies, lenalidomide has been shown 
to enhance the efficacy of the checkpoint blockade in 
contrasting tumor growth [90]. This evidence provided 
the scientific rationale for the combination of checkpoint 
inhibitors (pembrolizumab, anti-PD1, and durvalumab, 
anti-PD-L1) with IMiDs.
In a phase I, dose escalation trial, pembrolizumab 
combined with Rd (PembroRd) was tested in RRMM 
patients, after at least 2 prior regimens; of note, 76% 
patients were refractory to lenalidomide while 30% 
were double-refractory. Most common adverse events 
were thrombocytopenia (28%) and neutropenia (24%). 
Impressively, 76% of patients achieved at least a PR, with 
a median DOR of 10 months [91].
An ongoing phase II trial is exploring the safety 
and efficacy of pembrolizumab plus pomalidomide-
dexamethasone in RRMM [92]. A preliminary analysis of 
24 evaluable patients previously exposed to both IMiDs 
and PIs showed that the combination Pembrolizumab-
PD was well tolerated with most grade 3-4 adverse 
events being hematological. No IRRs were reported. 
Autoimmune toxicities were reported: hypotiroidism in 
8%, transaminitis in 8% and pneumonitis in 4% of the 
studied population. This combination also showed a good 
efficacy, with at least PR of 50%.
INTEGRATION OF DRUG 
COMBINATIONS INTO CLINICAL CARE 
AND FUTURE DIRECTIONS
At diagnosis, ASCT significantly improved PFS 
as compared with bortezomib- and lenalidomide-
based regimens without transplant, even if a survival 
benefit was not observed in all trials. ASCT-eligible 
patients usually receive a 3-drug induction treatment 
with IMID-PI and dexamethasone. Bortezomib-
thalidomide-dexamethasone (VTD) and bortezomib-
lenalidomide-dexamethasone (VRD) represent, to 
date, the standard induction approaches for transplant-
eligible patients;[93–95] however, new combinations 
are currently under investigation as induction options in 
these patients.
Preliminary results showed that induction treatment 
with ixazomib-lenalidomide-dexamethasone (IRD)[96] 
was very well tolerated (no grade 3-4 neuropathy, cardiac, 
liver or renal toxicities) and led to a at least a VGPR rate 
of 38%. After induction with Carfilzomib-Thalidomide-
dexamethasone (KTd)[97] or plus lenalidomide and 
dexamethasone (KRd)[98] more than 60% of patients 
achieved at least a VGPR, but cardiovascular toxicities 
have been reported.
Four-drug combinations may become the future 
strategy, with the incorporation of monoclonal antibodies 
as part of first-line and maintenance therapy to further 
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improve the depth and duration of response, both in young 
and elderly patients.
In the next few years, myeloma patients will 
have several therapeutic options at relapse; treatment 
choice should take into account patient’s fitness, disease 
aggressiveness, previous lines of therapies and sensibility 
or refractoriness to different compounds. When feasible, a 
multi-drug approach should be preferred.
Carfilzomib showed to be more effective than 
bortezomib, with a lower incidence of neuropathy and an 
increased cardiovascular toxicity in about 5% of patients. 
In combination with lenalidomide, KRd was active in 
patients previously exposed to bortezomib or lenalidomide 
and could be indicated in patients with an aggressive 
relapse [55]. Promising combinations with HDAC 
inhibitors, pomalidomide and several other compounds 
are being explored.
Ixazomib exerts a substantial activity both 
alone and in combination with IMIDs [59]. Its route 
of administration, (oral) and schedule (once-weekly) 
Table 4: New anti-myeloma compounds in early-phase studies in RRMM patients
Class Mechanism of action Drug Clinical studies
mTOR inhibitors Regulation of cell growth, protein synthesis and cell progression [101]
Everolimus
• Phase 1, single agent [102]
• Phase 1, in combination with lenalidomide 
[103]
Temsirolimus
• Phase 1, in combination with lenalidomide 
[104]
• Phase 1/2, in combination with bortezomib 
[105]
MEK1/2 inhibitor Inhibition of cell growth [106]
Trametinib
• Retrospective data, 2
• Phase 1, in combination with afuresertib in 
solid tumors and MM [107]
BRAF inhibitor
Inhibition of the costitutionally 
activated NRAS–BRAF–MEK–ERK 
pathway that leads to excessive 
cellular growth survival [108]
Vemurafenib
• Retrospective data in combination with 
cometinib [109]
• Phase 2, single agent in patients BRAF 
V600m-positive [110]
AKT inhibitor Inhibition of cell growth, apoptosis promotion [111–113]
Afuresertib
• Phase 1, in combination with trametinib in 
solid tumors and MM [107]
• Phase 1, single agent in advanced 
hematologic malignancies including MM [114]
anti IL-6
Promoting cell-apoptosis by blocking 
IL-6 through a chimeric anti-IL6 
monoclonal antibody [115]
Siltuximab
• Phase 2, single agent or in combination with 
dexamethasone [116]
• Phase 2, randomized, in combination with 
bortezomib or placebo [117]
• Phase 1, in combination with bortezomib and 
dexamethasone [118]
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make ixazomib an attractive option for elderly patients. 
Similarly, this agent might be attractive for maintenance 
therapy and, at relapse, Ixazomib combined with Rd may 
be particularly indicated for patients with indolent relapse.
Despite being active also as single agent, anti-CD38 
antibodies combined with other novel agents, such as 
lenalidomide and bortezomib, led to unprecedented results 
[86, 87]. For this reason daratumumab is likely to become 
part of the backbone treatment of both newly diagnosed 
and RRMM patients in the next future.
At relapse, the addition of elotuzumab to myeloma 
regimens, particularly to Rd, significantly improved PFS 
and time to next therapy [77]. Currently, elotuzumab 
could be considered for patients not treated with 
lenalidomide maintenance. In the future elotuzumab 
could be a preferable alternative as maintenance agent or 
in combination with current standard treatment at relapse, 
particularly in case of non-aggressive relapse.
Pomalidomide may be combined with MoAbs given 
the synergistic immunologic activity and the potency of 
this combination;[57] particularly when patients become 
refractory to lenalidomide or bortezomib.
A special consideration should be given to high-risk 
patients, who have benefited less from new drugs over the 
past decade. Based on data available today, combining a PI 
– such as carfilzomib or ixazomib - with lenalidomide and 
dexamethasone at least partially reverts the adverse effect 
of t(4;14) and del17p at diagnosis [99, 100]. Double ASCT 
plus bortezomib may improve outcome in patients with both 
t(4;14) and del17p. Next generation agents seem to overcome 
poor risk cytogenetics, but most of data was obtained in non-
randomized studies and longer follow-up is needed.
Unfortunately, in elderly patients there are no data 
suggesting an improved outcome in high-risk patients.
In conclusion, new agents, particularly when 
combined together, can overcome drug resistance, improve 
outcome and be a valuable strategy to address the clonal 
heterogeneity of MM.
A variety of new drugs, with different targets and 
mechanisms of action, have been developed and are 
currently under investigation in early phase trials; some 
of these compounds already showed an objective anti-
myeloma activity within the context of clinical trials 
(Table 4). It is therefore likely that multi-drug combinations 
will become a standard therapeutic approach for both newly 
diagnosed as well as relapsed/refractory myeloma.
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